{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:23:31Z","timestamp":1783653811789,"version":"3.55.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ERA4Health NANOTECMEC","award":["ERA4HEALTHNANO-293"],"award-info":[{"award-number":["ERA4HEALTHNANO-293"]}]},{"name":"Foundation for Cellular and Molecular Medicine","award":["Foundation for Cellular and Molecular Medicine"],"award-info":[{"award-number":["Foundation for Cellular and Molecular Medicine"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Galectins, a family of \u03b2-galactoside\u2013binding lectins, are key regulators of tumor progression, immune evasion, and therapy resistance in skin cancers. Among them, Galectin-1, Galectin-3, and Galectin-9 have been most extensively investigated for their multifaceted roles in shaping the tumor microenvironment. These proteins influence cancer cell proliferation, apoptosis, angiogenesis, and immune cell responses through both intracellular and extracellular mechanisms. Galectin-1 and Galectin-3 modulate immune checkpoint pathways and cancer-associated fibroblast activation, whereas Galectin-9 interacts with TIM-3 to induce T-cell exhaustion. Other family members, including Galectin-7 and Galectin-8, display context-dependent functions that may either promote or inhibit tumor development. Recent preclinical and early clinical trials targeting galectins, such as the Gal-3 inhibitors belapectin and GB1211, highlight their translational potential as adjuncts to immunotherapy. This review summarizes current knowledge on galectin expression and function in melanoma and non-melanoma skin cancers, emphasizing their contribution to immune escape and therapeutic resistance, as well as challenges and perspectives for galectin-targeted interventions.<\/jats:p>","DOI":"10.1186\/s40659-026-00695-w","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:15:49Z","timestamp":1778685349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of galectins in modulating the tumor microenvironment and driving metastasis in skin cancers"],"prefix":"10.1186","volume":"59","author":[{"given":"Mohsen","family":"Dabagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Ciceu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornel","family":"Balta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Consiglia","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolo","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanbattista","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8510-6653","authenticated-orcid":false,"given":"Anca","family":"Hermenean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad Mihail","family":"Voiculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"172","key":"695_CR1","doi-asserted-by":"publisher","first-page":"SE137","DOI":"10.4052\/tigg.1728.1SE","volume":"30","author":"J Iwaki","year":"2018","unstructured":"Iwaki J, Hirabayashi J. Carbohydrate-binding specificity of human galectins: an overview by frontal affinity chromatography. Trends Glycosci Glycotechnol. 2018;30(172):SE137\u201353. https:\/\/doi.org\/10.4052\/tigg.1728.1SE.","journal-title":"Trends Glycoscience Glycotechnology"},{"issue":"6","key":"695_CR2","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/biom13060902","volume":"13","author":"FCF Ko","year":"2023","unstructured":"Ko FCF, Yan S, Lee KW, Lam SK, Ho JCM. Chimera and tandem-repeat type galectins: the new targets for cancer immunotherapy. Biomolecules. 2023;13(6):902. https:\/\/doi.org\/10.3390\/biom13060902.","journal-title":"Biomolecules"},{"issue":"1","key":"695_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-025-00759-1","volume":"13","author":"N Zhang","year":"2025","unstructured":"Zhang N, Liu Q, Wang D, Wang X, Pan Z, Han B, et al. Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy. Biomark Res. 2025;13(1):49. https:\/\/doi.org\/10.1186\/s40364-025-00759-1.","journal-title":"Biomark Res"},{"key":"695_CR4","volume-title":"Cold Spring Harbor","author":"Essentials of glycobiology","year":"2022","unstructured":"Essentials of glycobiology. Cold Spring Harbor. 4th ed. New York: Cold Spring Harbor Laboratory Press; 2022.","edition":"4"},{"key":"695_CR5","doi-asserted-by":"publisher","unstructured":"B\u00e4nfer S, Schneider D, Dewes J, Strauss MT, Freibert SA, Heimerl T, et al. Molecular mechanism to recruit galectin-3 into multivesicular bodies for polarized exosomal secretion. Proc Natl Acad Sci USA. 2018;115(19). https:\/\/doi.org\/10.1073\/pnas.1718921115.","DOI":"10.1073\/pnas.1718921115"},{"issue":"1","key":"695_CR6","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1038\/s41467-025-59605-5","volume":"16","author":"W Zhang","year":"2025","unstructured":"Zhang W, Ji C, Li X, He T, Jiang W, Liu Y, et al. Autophagy-independent role of ATG9A vesicles as carriers for galectin-9 secretion. Nat Commun. 2025;16(1):4259. https:\/\/doi.org\/10.1038\/s41467-025-59605-5.","journal-title":"Nat Commun"},{"issue":"11","key":"695_CR7","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1093\/glycob\/cwl025","volume":"16","author":"I Camby","year":"2006","unstructured":"Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology. 2006;16(11):R137\u201357. https:\/\/doi.org\/10.1093\/glycob\/cwl025.","journal-title":"Glycobiology"},{"key":"695_CR8","doi-asserted-by":"publisher","first-page":"25023309","DOI":"10.1016\/j.jid.2025.07.020","volume":"S0022202X","author":"K Danesh","year":"2025","unstructured":"Danesh K, Lin FJ, Chen HL, Liu FT. Galectins in inflammatory skin diseases: mechanisms and therapeutic potential. J Invest Dermatology. 2025;S0022202X:25023309. https:\/\/doi.org\/10.1016\/j.jid.2025.07.020.","journal-title":"J Invest Dermatology"},{"issue":"43","key":"695_CR9","doi-asserted-by":"publisher","first-page":"15975","DOI":"10.1073\/pnas.0603883103","volume":"103","author":"VLJL Thijssen","year":"2006","unstructured":"Thijssen VLJL, Postel R, Brandwijk RJMGE, Dings RPM, Nesmelova I, Satijn S, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA. 2006;103(43):15975\u201380. https:\/\/doi.org\/10.1073\/pnas.0603883103.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"695_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.devcel.2019.10.025","volume":"52","author":"J Jia","year":"2020","unstructured":"Jia J, Claude-Taupin A, Gu Y, Choi SW, Peters R, Bissa B, et al. Galectin-3 Coordinates a Cellular System for Lysosomal Repair and Removal. Dev Cell. 2020;52(1):69\u2013e878. https:\/\/doi.org\/10.1016\/j.devcel.2019.10.025.","journal-title":"Dev Cell"},{"issue":"12","key":"695_CR11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245\u201352. https:\/\/doi.org\/10.1038\/ni1271.","journal-title":"Nat Immunol"},{"issue":"6","key":"695_CR12","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","volume":"10","author":"Y Lv","year":"2023","unstructured":"Lv Y, Ma X, Ma Y, Du Y, Feng J. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis. 2023;10(6):2366\u201382. https:\/\/doi.org\/10.1016\/j.gendis.2022.05.020.","journal-title":"Genes Dis"},{"key":"695_CR13","doi-asserted-by":"publisher","unstructured":"Mohammed NBB, Antonopoulos A, Dell A, Haslam SM, Dimitroff CJ. The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma. Advances in Cancer Research . Elsevier; 2023 . 157:157-193.Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X22000525https:\/\/doi.org\/10.1016\/bs.acr.2022.06.001","DOI":"10.1016\/bs.acr.2022.06.001"},{"issue":"1","key":"695_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.molcel.2018.03.009","volume":"70","author":"J Jia","year":"2018","unstructured":"Jia J, Abudu YP, Claude-Taupin A, Gu Y, Kumar S, Choi SW, et al. Galectins Control mTOR in response to endomembrane damage. Mol Cell. 2018;70(1):120\u2013e1358. https:\/\/doi.org\/10.1016\/j.molcel.2018.03.009.","journal-title":"Mol Cell"},{"issue":"7385","key":"695_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/nature10744","volume":"482","author":"TLM Thurston","year":"2012","unstructured":"Thurston TLM, Wandel MP, Von Muhlinen N, Foeglein \u00c1, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature. 2012;482(7385):414\u20138. https:\/\/doi.org\/10.1038\/nature10744.","journal-title":"Nature"},{"issue":"4","key":"695_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41418-022-01108-7","volume":"30","author":"NA Pinto","year":"2023","unstructured":"Pinto NA, Abba MC, Laporte L, P\u00e9rez S\u00e1ez JM, Blidner AG, Torres NI, et al. Galectin-7 reprograms skin carcinogenesis by fostering innate immune evasive programs. Cell Death Differ. 2023;30(4):906\u201321. https:\/\/doi.org\/10.1038\/s41418-022-01108-7.","journal-title":"Cell Death Differ"},{"issue":"4","key":"695_CR17","doi-asserted-by":"publisher","first-page":"e002371","DOI":"10.1136\/jitc-2021-002371","volume":"9","author":"BD Curti","year":"2021","unstructured":"Curti BD, Koguchi Y, Leidner RS, Rolig AS, Sturgill ER, Sun Z, et al. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. J Immunother Cancer. 2021;9(4):e002371. https:\/\/doi.org\/10.1136\/jitc-2021-002371.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"695_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00280-023-04513-y","volume":"91","author":"V Aslanis","year":"2023","unstructured":"Aslanis V, Slack RJ, MacKinnon AC, McClinton C, Tantawi S, Gravelle L, et al. Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer Chemother Pharmacol. 2023;91(3):267\u201380. https:\/\/doi.org\/10.1007\/s00280-023-04513-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"695_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s43556-024-00209-8","volume":"5","author":"ZW Yu","year":"2024","unstructured":"Yu ZW, Zheng M, Fan HY, Liang XH, Tang YL. Ultraviolet (UV) radiation: a double-edged sword in cancer development and therapy. Mol Biomed. 2024;5(1):49. https:\/\/doi.org\/10.1186\/s43556-024-00209-8.","journal-title":"Mol Biomed"},{"issue":"9","key":"695_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang Q, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2023;14(9):587. https:\/\/doi.org\/10.1038\/s41419-023-06110-6.","journal-title":"Cell Death Dis"},{"issue":"8","key":"695_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20140692","volume":"211","author":"D \u00d6hlund","year":"2014","unstructured":"\u00d6hlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211(8):1503\u201323. https:\/\/doi.org\/10.1084\/jem.20140692.","journal-title":"J Exp Med"},{"issue":"1","key":"695_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","volume":"39","author":"X Jiang","year":"2020","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020;39(1):204. https:\/\/doi.org\/10.1186\/s13046-020-01709-5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"13","key":"695_CR23","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995. https:\/\/doi.org\/10.3390\/ijms22136995.","journal-title":"Int J Mol Sci"},{"key":"695_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fonc.2018.00003","volume":"8","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Kambayashi Y, Fujisawa Y, Hidaka T, Aiba S. Tumor-associated macrophages: therapeutic targets for skin cancer. Front Oncol. 2018;8:3. https:\/\/doi.org\/10.3389\/fonc.2018.00003.","journal-title":"Front Oncol"},{"issue":"10","key":"695_CR25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014\u201322. https:\/\/doi.org\/10.1038\/ni.2703.","journal-title":"Nat Immunol"},{"issue":"1","key":"695_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"695_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","volume":"16","author":"ME Shaul","year":"2019","unstructured":"Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601\u201320. https:\/\/doi.org\/10.1038\/s41571-019-0222-4.","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"695_CR28","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/febs.14818","volume":"286","author":"AD Theocharis","year":"2019","unstructured":"Theocharis AD, Manou D, Karamanos NK. The extracellular matrix as a multitasking player in disease. FEBS J. 2019;286(15):2830\u201369. https:\/\/doi.org\/10.1111\/febs.14818.","journal-title":"FEBS J"},{"key":"695_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fcell.2018.00017","volume":"6","author":"JM Northcott","year":"2018","unstructured":"Northcott JM, Dean IS, Mouw JK, Weaver VM. Feeling stress: the mechanics of cancer progression and aggression. Front Cell Dev Biol. 2018;6:17. https:\/\/doi.org\/10.3389\/fcell.2018.00017.","journal-title":"Front Cell Dev Biol"},{"issue":"6212","key":"695_CR30","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.1253735","volume":"346","author":"JA Lo","year":"2014","unstructured":"Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science. 2014;346(6212):945\u20139. doi:10.1126\/science.1253735 PubMed PMID: 25414302; PubMed Central PMCID: PMC4701046.","journal-title":"Science"},{"issue":"2","key":"695_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","volume":"24","author":"J Bauer","year":"2011","unstructured":"Bauer J, B\u00fcttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011;24(2):345\u201351. https:\/\/doi.org\/10.1111\/j.1755-148X.2011.00837.x","journal-title":"Pigment Cell Melanoma Res"},{"issue":"22","key":"695_CR32","doi-asserted-by":"publisher","first-page":"10124","DOI":"10.1073\/pnas.88.22.10124","volume":"88","author":"DE Brash","year":"1991","unstructured":"Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88(22):10124\u20138. https:\/\/doi.org\/10.1073\/pnas.88.22.10124.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"695_CR33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/cells14040308","volume":"14","author":"G Ghajar-Rahimi","year":"2025","unstructured":"Ghajar-Rahimi G, Yusuf N, Xu H. Ultraviolet radiation-induced tolerogenic dendritic cells in skin: insights and mechanisms. Cells. 2025;14(4):308. https:\/\/doi.org\/10.3390\/cells14040308.","journal-title":"Cells"},{"key":"695_CR34","doi-asserted-by":"publisher","unstructured":"Maldonado RA, Von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. In: Advances in immunology ; 2010 . 108:111-65.. Available from: https:\/\/doi.org\/10.1016\/B978-0-12-380995-7.00004-5","DOI":"10.1016\/B978-0-12-380995-7.00004-5"},{"issue":"1","key":"695_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2045-3701-1-20","volume":"1","author":"R Kushwah","year":"2011","unstructured":"Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells. Cell Biosci. 2011;1(1):20. https:\/\/doi.org\/10.1186\/2045-3701-1-20.","journal-title":"Cell Biosci"},{"key":"695_CR36","doi-asserted-by":"publisher","first-page":"1040163","DOI":"10.3389\/fphar.2022.1040163","volume":"13","author":"Y Wen","year":"2022","unstructured":"Wen Y, Zhu Y, Zhang C, Yang X, Gao Y, Li M, et al. Chronic inflammation, cancer development and immunotherapy. Front Pharmacol. 2022;13:1040163. https:\/\/doi.org\/10.3389\/fphar.2022.1040163.","journal-title":"Front Pharmacol"},{"issue":"1","key":"695_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Sig Transduct Target Ther. 2021;6(1):263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"695_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/09205063.2022.2106647","volume":"34","author":"G Tripathi","year":"2023","unstructured":"Tripathi G, Ho VH, Jung HI, Lee BT. Physico-mechanical and in-vivo evaluations of tri-layered alginate-gelatin\/polycaprolactone-gelatin-\u03b2-TCP membranes for guided bone regeneration. J Biomater Sci Polym Ed. 2023;34(1):18\u201334. https:\/\/doi.org\/10.1080\/09205063.2022.2106647.","journal-title":"J Biomater Sci Polym Ed"},{"key":"695_CR39","doi-asserted-by":"publisher","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","volume":"14","author":"U Basak","year":"2023","unstructured":"Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S, et al. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023;14:1295257. https:\/\/doi.org\/10.3389\/fimmu.2023.1295257.","journal-title":"Front Immunol"},{"issue":"7","key":"695_CR40","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/cr.2013.75","volume":"23","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu ZG. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 2013;23(7):898\u2013914. https:\/\/doi.org\/10.1038\/cr.2013.75.","journal-title":"Cell Res"},{"key":"695_CR41","doi-asserted-by":"publisher","unstructured":"Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C, Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy? Cancers (Basel). 2021;13(14):3466. https:\/\/doi.org\/10.3390\/cancers13143466","DOI":"10.3390\/cancers13143466"},{"issue":"3","key":"695_CR42","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.3892\/ol.2017.6497","volume":"14","author":"L Tao","year":"2017","unstructured":"Tao L, Huang G, Song H, Chen Y, Chen L. Cancer associated fibroblasts: an essential role in the tumor microenvironment. Oncol Lett. 2017;14(3):2611\u201320. https:\/\/doi.org\/10.3892\/ol.2017.6497.","journal-title":"Oncol Lett"},{"key":"695_CR43","doi-asserted-by":"publisher","first-page":"756001","DOI":"10.3389\/fonc.2021.756001","volume":"11","author":"F Huang","year":"2021","unstructured":"Huang F, Santinon F, Flores Gonz\u00e1lez RE, Del Rinc\u00f3n SV. Melanoma plasticity: promoter of metastasis and resistance to therapy. Front Oncol. 2021;11:756001. https:\/\/doi.org\/10.3389\/fonc.2021.756001.","journal-title":"Front Oncol"},{"issue":"1","key":"695_CR44","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1038\/s41467-018-05047-1","volume":"9","author":"L Brochez","year":"2018","unstructured":"Brochez L, Meireson A, Chevolet I, Sundahl N, Ost P, Kruse V, Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. Nat Commun. 2018;9(1):2921. https:\/\/doi.org\/10.1038\/s41467-018-05047-1.","journal-title":"Nat Commun"},{"issue":"1","key":"695_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1476-4598-11-76","volume":"11","author":"J Ho","year":"2012","unstructured":"Ho J, De Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer. 2012;11(1):76. https:\/\/doi.org\/10.1186\/1476-4598-11-76.","journal-title":"Mol Cancer"},{"issue":"7510","key":"695_CR46","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nature13298","volume":"511","author":"A Viros","year":"2014","unstructured":"Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature. 2014;511(7510):478\u201382. https:\/\/doi.org\/10.1038\/nature13298.","journal-title":"Nature"},{"issue":"9","key":"695_CR47","doi-asserted-by":"publisher","first-page":"e202101135","DOI":"10.26508\/lsa.202101135","volume":"4","author":"RL Bowman","year":"2021","unstructured":"Bowman RL, Hennessey RC, Weiss TJ, Tallman DA, Crawford ER, Murphy BM, et al. UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma. Life Sci Alliance. 2021;4(9):e202101135. https:\/\/doi.org\/10.26508\/lsa.202101135.","journal-title":"Life Sci Alliance"},{"key":"695_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2133.2009.09458.x","volume":"161","author":"PM Rodust","year":"2009","unstructured":"Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J. UV-induced squamous cell carcinoma - a role for antiapoptotic signalling pathways. Br J Dermatol. 2009;161:107\u201315. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09458.x.","journal-title":"Br J Dermatol"},{"key":"695_CR49","doi-asserted-by":"publisher","unstructured":"Paulo MS, Symanzik C, \u00c1dam B, Gobba F, Kezic S, Van Der Molen HF et al. Risk of cutaneous squamous cell carcinoma due to occupational exposure to solar ultraviolet radiation: Protocol for a systematic review and meta-analysis. Rota M, editor. PLoS ONE. 2023;18(3):e0282664. https:\/\/doi.org\/10.1371\/journal.pone.0282664","DOI":"10.1371\/journal.pone.0282664"},{"key":"695_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13005-016-0106-0","volume":"12","author":"L Feller","year":"2016","unstructured":"Feller L, Khammissa RaG, Kramer B, Altini M, Lemmer J. Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head Face Med. 2016;12:11. https:\/\/doi.org\/10.1186\/s13005-016-0106-0.","journal-title":"Head Face Med"},{"issue":"3","key":"695_CR51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ijc.28391","volume":"134","author":"EP Salerno","year":"2014","unstructured":"Salerno EP, Olson WC, McSkimming C, Shea S, Slingluff CL. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer. 2014;134(3):563\u201374. https:\/\/doi.org\/10.1002\/ijc.28391.","journal-title":"Int J Cancer"},{"issue":"1","key":"695_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1476-9255-9-46","volume":"9","author":"TH Gasparoto","year":"2012","unstructured":"Gasparoto TH, De Oliveira CE, De Freitas LT, Pinheiro CR, Ramos RN, Da Silva AL, et al. Inflammatory events during murine squamous cell carcinoma development. J Inflamm. 2012;9(1):46. https:\/\/doi.org\/10.1186\/1476-9255-9-46.","journal-title":"J Inflamm"},{"issue":"4","key":"695_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5021\/ad.22.042","volume":"35","author":"C Zilberg","year":"2023","unstructured":"Zilberg C, Lyons JG, Gupta R, Damian DL. The immune microenvironment in basal cell carcinoma. Ann Dermatol. 2023;35(4):243. https:\/\/doi.org\/10.5021\/ad.22.042.","journal-title":"Ann Dermatol"},{"key":"695_CR54","doi-asserted-by":"publisher","first-page":"122563","DOI":"10.1016\/j.lfs.2024.122563","volume":"345","author":"M Malekan","year":"2024","unstructured":"Malekan M, Haass NK, Rokni GR, Gholizadeh N, Ebrahimzadeh MA, Kazeminejad A. VEGF\/VEGFR axis and its signaling in melanoma: current knowledge toward therapeutic targeting agents and future perspectives. Life Sci. 2024;345:122563. https:\/\/doi.org\/10.1016\/j.lfs.2024.122563.","journal-title":"Life Sci"},{"key":"695_CR55","doi-asserted-by":"publisher","first-page":"651501","DOI":"10.1155\/2014\/651501","volume":"2014","author":"I Pastushenko","year":"2014","unstructured":"Pastushenko I, Gracia-Caza\u00f1a T, Vicente-Arregui S, Van den Eynden GG, Ara M, Vermeulen PB, et al. Squamous cell carcinomas of the skin explore angiogenesis-independent mechanisms of tumour vascularization. J Skin Cancer. 2014;2014:651501. https:\/\/doi.org\/10.1155\/2014\/651501.","journal-title":"J Skin Cancer"},{"issue":"6","key":"695_CR56","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1021\/mp200421k","volume":"8","author":"EH Flach","year":"2011","unstructured":"Flach EH, Rebecca VW, Herlyn M, Smalley KSM, Anderson ARA. Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm. 2011;8(6):2039\u201349. https:\/\/doi.org\/10.1021\/mp200421k.","journal-title":"Mol Pharm"},{"issue":"3","key":"695_CR57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/hed.23312","volume":"36","author":"SE Wheeler","year":"2014","unstructured":"Wheeler SE, Shi H, Lin F, Dasari S, Bednash J, Thorne S, et al. Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models. Head Neck. 2014;36(3):385\u201392. https:\/\/doi.org\/10.1002\/hed.23312.","journal-title":"Head Neck"},{"issue":"1","key":"695_CR58","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s12885-017-3663-0","volume":"17","author":"SH Omland","year":"2017","unstructured":"Omland SH, Wettergren EE, Mollerup S, Asplund M, Mourier T, Hansen AJ, et al. Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin. BMC Cancer. 2017;17(1):675. https:\/\/doi.org\/10.1186\/s12885-017-3663-0.","journal-title":"BMC Cancer"},{"issue":"1","key":"695_CR59","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1038\/s41467-024-53908-9","volume":"15","author":"A Forsthuber","year":"2024","unstructured":"Forsthuber A, Aschenbrenner B, Korosec A, Jacob T, Annusver K, Krajic N, et al. Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy. Nat Commun. 2024;15(1):9678. https:\/\/doi.org\/10.1038\/s41467-024-53908-9.","journal-title":"Nat Commun"},{"issue":"5","key":"695_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/ijd.14850","volume":"59","author":"SM Arias-Mejias","year":"2020","unstructured":"Arias-Mejias SM, Warda KY, Quattrocchi E, Alonso-Quinones H, Sominidi-Damodaran S, Meves A. The role of integrins in melanoma: a review. Int J Dermatol. 2020;59(5):525\u201334. https:\/\/doi.org\/10.1111\/ijd.14850.","journal-title":"Int J Dermatol"},{"issue":"2","key":"695_CR61","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10555-005-1572-1","volume":"24","author":"S Kuphal","year":"2005","unstructured":"Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005;24(2):195\u2013222. https:\/\/doi.org\/10.1007\/s10555-005-1572-1.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"695_CR62","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1523-1747.2000.00068.x","volume":"115","author":"UB Hofmann","year":"2000","unstructured":"Hofmann UB, Westphal JR, Van Muijen GNP, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000;115(3):337\u201344. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00068.x.","journal-title":"J Invest Dermatology"},{"issue":"11","key":"695_CR63","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3390\/cancers13112759","volume":"13","author":"A Fejza","year":"2021","unstructured":"Fejza A, Camicia L, Poletto E, Carobolante G, Mongiat M, Andreuzzi E. ECM remodeling in squamous cell carcinoma of the aerodigestive tract: pathways for cancer dissemination and emerging biomarkers. Cancers. 2021;13(11):2759. https:\/\/doi.org\/10.3390\/cancers13112759.","journal-title":"Cancers"},{"key":"695_CR64","doi-asserted-by":"publisher","first-page":"864302","DOI":"10.3389\/fmolb","volume":"9","author":"JE Fromme","year":"2022","unstructured":"Fromme JE, Zigrino P. The role of extracellular matrix remodeling in skin tumor progression and therapeutic resistance. Front Mol Biosci. 2022;9:864302. https:\/\/doi.org\/10.3389\/fmolb.2022.864302.","journal-title":"Front Mol Biosci"},{"issue":"8","key":"695_CR65","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/1744666X.2024.2326626","volume":"20","author":"S Habib","year":"2024","unstructured":"Habib S, Osborn G, Willsmore Z, Chew MW, Jakubow S, Fitzpatrick A, et al. Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma. Expert Rev Clin Immunol. 2024;20(8):895\u2013911. https:\/\/doi.org\/10.1080\/1744666X.2024.2326626","journal-title":"Expert Rev Clin Immunol"},{"issue":"200","key":"695_CR66","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116. https:\/\/doi.org\/10.1126\/scitranslmed.3006504.","journal-title":"Sci Transl Med"},{"issue":"7","key":"695_CR67","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3390\/cancers12071860","volume":"12","author":"S Khou","year":"2020","unstructured":"Khou S, Popa A, Luci C, Bihl F, Meghraoui-Kheddar A, Bourdely P, et al. Tumor-associated neutrophils dampen adaptive immunity and promote cutaneous squamous cell carcinoma development. Cancers (Basel). 2020;12(7):1860. https:\/\/doi.org\/10.3390\/cancers12071860.","journal-title":"Cancers (Basel)"},{"key":"695_CR68","doi-asserted-by":"publisher","first-page":"959747","DOI":"10.3389\/fphys.2022.959747","volume":"13","author":"Y Xue","year":"2022","unstructured":"Xue Y, Song X, Fan S, Deng R. The role of tumor-associated macrophages in oral squamous cell carcinoma. Front Physiol. 2022;13:959747. https:\/\/doi.org\/10.3389\/fphys.2022.959747. PubMed PMID: 36105288; PubMed Central PMCID: PMC9464857.","journal-title":"Front Physiol"},{"key":"695_CR69","doi-asserted-by":"publisher","first-page":"1145268","DOI":"10.3389\/fimmu.2023.1145268","volume":"14","author":"NI Kapetanakis","year":"2023","unstructured":"Kapetanakis NI, Busson P. Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies. Front Immunol. 2023;14:1145268. https:\/\/doi.org\/10.3389\/fimmu.2023.1145268.","journal-title":"Front Immunol"},{"issue":"9","key":"695_CR70","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1038\/jid.2012.142","volume":"132","author":"V Mathieu","year":"2012","unstructured":"Mathieu V, De Lassalle EM, Toelen J, Mohr T, Bellahc\u00e8ne A, Van Goietsenoven G, et al. Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatology. 2012;132(9):2245\u201354. https:\/\/doi.org\/10.1038\/jid.2012.142.","journal-title":"J Invest Dermatology"},{"issue":"1","key":"695_CR71","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0304-4165(99)00177-4","volume":"1473","author":"R Hughes","year":"1999","unstructured":"Hughes R. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochimica et Biophysica Acta (BBA) -. Gen Subj. 1999;1473(1):172\u201385. https:\/\/doi.org\/10.1016\/S0304-4165(99)00177-4.","journal-title":"Gen Subj"},{"issue":"1","key":"695_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40659-024-00490-5","volume":"57","author":"E Perez-Moreno","year":"2024","unstructured":"Perez-Moreno E, Oyanadel C, De La Pe\u00f1a A, Hern\u00e1ndez R, P\u00e9rez-Molina F, Metz C, et al. Galectins in epithelial-mesenchymal transition: roles and mechanisms contributing to tissue repair, fibrosis and cancer metastasis. Biol Res. 2024;57(1):14. https:\/\/doi.org\/10.1186\/s40659-024-00490-5.","journal-title":"Biol Res"},{"issue":"12","key":"695_CR73","doi-asserted-by":"publisher","first-page":"105400","DOI":"10.1016\/j.jbc.2023.105400","volume":"299","author":"MF Troncoso","year":"2023","unstructured":"Troncoso MF, Elola MT, Blidner AG, Sarrias L, Espelt MV, Rabinovich GA. The universe of galectin-binding partners and their functions in health and disease. J Biol Chem. 2023;299(12):105400. https:\/\/doi.org\/10.1016\/j.jbc.2023.105400.","journal-title":"J Biol Chem"},{"issue":"11","key":"695_CR74","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/j.1600-0854.2009.00981.x","volume":"10","author":"JW Dennis","year":"2009","unstructured":"Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive regulation at the cell surface by N -Glycosylation. Traffic. 2009;10(11):1569\u201378. https:\/\/doi.org\/10.1111\/j.1600-0854.2009.00981.x.","journal-title":"Traffic"},{"issue":"1","key":"695_CR75","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cell.2007.01.049","volume":"129","author":"KS Lau","year":"2007","unstructured":"Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, et al. Complex N-Glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007;129(1):123\u201334. https:\/\/doi.org\/10.1016\/j.cell.2007.01.049.","journal-title":"Cell"},{"issue":"13","key":"695_CR76","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1242\/jcs.151159","volume":"128","author":"IR Nabi","year":"2015","unstructured":"Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci. 2015;128(13):2213\u20139. https:\/\/doi.org\/10.1242\/jcs.151159.","journal-title":"J Cell Sci"},{"issue":"3","key":"695_CR77","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1046\/j.1432-0436.1998.6330159.x","volume":"63","author":"T Magnaldo","year":"1998","unstructured":"Magnaldo T, Fowlis D, Darmon M. Galectin-7, a marker of all types of stratified epithelia. Differentiation. 1998;63(3):159\u201368. https:\/\/doi.org\/10.1046\/j.1432-0436.1998.6330159.x.","journal-title":"Differentiation"},{"issue":"5","key":"695_CR78","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1074\/jbc.M109360200","volume":"277","author":"I Kuwabara","year":"2002","unstructured":"Kuwabara I, Kuwabara Y, Yang RY, Schuler M, Green DR, Zuraw BL, et al. Galectin-7 (PIG1) Exhibits pro-apoptotic function through jnk activation and mitochondrial cytochrome crelease. J Biol Chem. 2002;277(5):3487\u201397. https:\/\/doi.org\/10.1074\/jbc.M109360200.","journal-title":"J Biol Chem"},{"issue":"7\u20139","key":"695_CR79","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1023\/B:GLYC.0000014081.55445.af","volume":"19","author":"Y Zick","year":"2002","unstructured":"Zick Y, Eisenstein M, Goren RA, Hadari YR, Levy Y, Ronen D. Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconj J. 2002;19(7\u20139):517\u201326. https:\/\/doi.org\/10.1023\/B:GLYC.0000014081.55445.af.","journal-title":"Glycoconj J"},{"key":"695_CR80","doi-asserted-by":"publisher","unstructured":"Thijssen VL, Heusschen R, Caers J, Griffioen AW. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2015;1855(2):235\u201347. https:\/\/doi.org\/10.1016\/j.bbcan.2015.03.003","DOI":"10.1016\/j.bbcan.2015.03.003"},{"issue":"4","key":"695_CR81","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","volume":"1760","author":"J Dumic","year":"2006","unstructured":"Dumic J, Dabelic S, Fl\u00f6gel M. Galectin-3: An open-ended story. Biochim et Biophys Acta (BBA) - Gen Subj. 2006;1760(4):616\u201335. https:\/\/doi.org\/10.1016\/j.bbagen.2005.12.020.","journal-title":"Biochim et Biophys Acta (BBA) - Gen Subj"},{"issue":"10","key":"695_CR82","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/glycob\/cwu","volume":"24","author":"T Funasaka","year":"2014","unstructured":"Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. Glycobiology. 2014;24(10):886\u201391. https:\/\/doi.org\/10.1093\/glycob\/cwu.","journal-title":"Glycobiology"},{"issue":"12","key":"695_CR83","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.3390\/ijms18122760","volume":"18","author":"T Advedissian","year":"2017","unstructured":"Advedissian T, Deshayes F, Viguier M. Galectin-7 in epithelial homeostasis and carcinomas. IJMS. 2017;18(12):2760. https:\/\/doi.org\/10.3390\/ijms18122760.","journal-title":"IJMS"},{"issue":"3","key":"695_CR84","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3892\/ol.2017.5649","volume":"13","author":"JP Guo","year":"2017","unstructured":"Guo JP, Li XG. Galectin-7 promotes the invasiveness of human oral squamous cell carcinoma cells via activation of ERK and JNK signaling. Oncol Lett. 2017;13(3):1919\u201324. https:\/\/doi.org\/10.3892\/ol.2017.5649.","journal-title":"Oncol Lett"},{"key":"695_CR85","doi-asserted-by":"publisher","first-page":"1614277","DOI":"10.3389\/falgy.2025.1614277","volume":"6","author":"L Wang","year":"2025","unstructured":"Wang L, Zhang C, Ji J, Jiao Q. Galectin-9: diverse roles in skin disease. Front Allergy. 2025;6:1614277. https:\/\/doi.org\/10.3389\/falgy.2025.1614277.","journal-title":"Front Allergy"},{"issue":"7","key":"695_CR86","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/jid.2015.95","volume":"135","author":"EM Yazawa","year":"2015","unstructured":"Yazawa EM, Geddes-Sweeney JE, Cedeno-Laurent F, Walley KC, Barthel SR, Opperman MJ, et al. Melanoma cell galectin-1 ligands functionally correlate with malignant potential. J Invest Dermatol. 2015;135(7):1849\u201362. https:\/\/doi.org\/10.1038\/jid.2015.95.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"695_CR87","doi-asserted-by":"publisher","first-page":"e2214350120","DOI":"10.1073\/pnas.2214350120","volume":"120","author":"N Bannoud","year":"2023","unstructured":"Bannoud N, Stupirski JC, Cagnoni AJ, Hockl PF, P\u00e9rez S\u00e1ez JM, Garc\u00eda PA, et al. Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology. Proc Natl Acad Sci U S A. 2023;120(3):e2214350120. https:\/\/doi.org\/10.1073\/pnas.2214350120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"695_CR88","doi-asserted-by":"publisher","unstructured":"Zhang. Increased expression of galectin-1 is associated with human oral squamous cell carcinoma development. Oncol Rep. 2009;21(4). https:\/\/doi.org\/10.3892\/or_00000312.","DOI":"10.3892\/or_00000312"},{"issue":"22","key":"695_CR89","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1158\/0008-5472.CAN-12-2424","volume":"72","author":"RR Braeuer","year":"2012","unstructured":"Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012;72(22):5757\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2424.","journal-title":"Cancer Res"},{"issue":"3","key":"695_CR90","doi-asserted-by":"publisher","first-page":"322","DOI":"10.26502\/jcsct.5079169","volume":"6","author":"S Pokhare","year":"2022","unstructured":"Pokhare S, Sharma UC, Attwood K, Mansoor S. Clinical significance of galectin-3 expression in squamous cell carcinoma of lung. J Cancer Sci Clin Ther. 2022;6(3):322\u20137. https:\/\/doi.org\/10.26502\/jcsct.5079169.","journal-title":"J Cancer Sci Clin Ther"},{"key":"695_CR91","doi-asserted-by":"publisher","unstructured":"Castronovo V, Liu FT, Van Den Brule FA. Decreased expression of galectin-3 in basal cell carcinoma of the skin. Int J Oncol. 1999 Jul;1. https:\/\/doi.org\/10.3892\/ijo.15.1.67.","DOI":"10.3892\/ijo.15.1.67"},{"issue":"2","key":"695_CR92","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.prp.2008.09.001","volume":"205","author":"N Kapucuoglu","year":"2009","unstructured":"Kapucuoglu N, Basak PY, Bircan S, Sert S, Akkaya VB. Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol - Res Pract. 2009;205(2):97\u2013103. https:\/\/doi.org\/10.1016\/j.prp.2008.09.001.","journal-title":"Pathol - Res Pract"},{"issue":"6","key":"695_CR93","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/ijc.10436","volume":"99","author":"T Kageshita","year":"2002","unstructured":"Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Intl J Cancer. 2002;99(6):809\u201316. https:\/\/doi.org\/10.1002\/ijc.10436.","journal-title":"Intl J Cancer"},{"issue":"20","key":"695_CR94","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1158\/0008-5472.CAN-22-0970","volume":"82","author":"T Schatton","year":"2022","unstructured":"Schatton T, Itoh Y, Martins C, Rasbach E, Singh P, Silva M, et al. Inhibition of melanoma cell\u2013intrinsic tim-3 stimulates mapk-dependent tumorigenesis. Cancer Res. 2022;82(20):3774\u201384. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0970.","journal-title":"Cancer Res"},{"issue":"2","key":"695_CR95","doi-asserted-by":"publisher","first-page":"195","DOI":"10.30699\/IJP.2021.121140.2318","volume":"16","author":"M Ghasemi","year":"2021","unstructured":"Ghasemi M, Vahedi Larijani L, Yazdani-Charati J, Kamali Hakim E. Reduced expression of galectin-8 may contribute in carcinogenic pathway of head and neck squamous cell carcinoma. Iran J Pathol. 2021;16(2):195\u2013204. https:\/\/doi.org\/10.30699\/IJP.2021.121140.2318.","journal-title":"Iran J Pathol"},{"issue":"11","key":"695_CR96","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/j.1600-0854.2009.00981.x","volume":"10","author":"JW Dennis","year":"2009","unstructured":"Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive regulation at the cell surface by N -Glycosylation. Traffic. 2009;10(11):1569\u201378. https:\/\/doi.org\/10.1111\/j.1600-0854.2009.00981.x.","journal-title":"Traffic"},{"issue":"10","key":"695_CR97","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/glycob\/cwn071","volume":"18","author":"KS Lau","year":"2008","unstructured":"Lau KS, Dennis JW. N-Glycans in cancer progression. Glycobiology. 2008;18(10):750\u201360. https:\/\/doi.org\/10.1093\/glycob\/cwn071.","journal-title":"Glycobiology"},{"issue":"12","key":"695_CR98","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.4049\/jimmunol.1502532","volume":"198","author":"K Nomura","year":"2017","unstructured":"Nomura K, Vilalta A, Allendorf DH, Hornik TC, Brown GC. Activated microglia desialylate and phagocytose cells via neuraminidase, Galectin-3, and mer tyrosine kinase. J Immunol. 2017;198(12):4792\u2013801. https:\/\/doi.org\/10.4049\/jimmunol.1502532.","journal-title":"J Immunol"},{"issue":"4","key":"695_CR99","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/diseases10040114","volume":"10","author":"S Nag","year":"2022","unstructured":"Nag S, Mandal A, Joshi A, Jain N, Srivastava RS, Singh S, et al. Sialyltransferases and neuraminidases: potential targets for cancer treatment. Diseases. 2022;10(4):114. https:\/\/doi.org\/10.3390\/diseases10040114.","journal-title":"Diseases"},{"key":"695_CR100","doi-asserted-by":"publisher","first-page":"1166916","DOI":"10.3389\/fcell.2023.1166916","volume":"11","author":"S Zhou","year":"2023","unstructured":"Zhou S, Lu J, Liu S, Shao J, Liu Z, Li J, et al. Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors. Front Cell Dev Biol. 2023;11:1166916. https:\/\/doi.org\/10.3389\/fcell.2023.1166916.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"695_CR101","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3390\/biomedicines9091159","volume":"9","author":"CH Li","year":"2021","unstructured":"Li CH, Chang YC, Chan MH, Yang YF, Liang SM, Hsiao M. Galectins in cancer and the microenvironment: functional roles, therapeutic developments, and perspectives. Biomedicines. 2021;9(9):1159. https:\/\/doi.org\/10.3390\/biomedicines9091159.","journal-title":"Biomedicines"},{"issue":"4","key":"695_CR102","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jid.2021.09.010","volume":"142","author":"L Van Hove","year":"2022","unstructured":"Van Hove L, Hoste E. Activation of fibroblasts in skin cancer. J Invest Dermatology. 2022;142(4):1026\u201331. https:\/\/doi.org\/10.1016\/j.jid.2021.09.010.","journal-title":"J Invest Dermatology"},{"issue":"17","key":"695_CR103","doi-asserted-by":"publisher","first-page":"13482","DOI":"10.3390\/ijms241713482","volume":"24","author":"K Knipper","year":"2023","unstructured":"Knipper K, Lyu S, Quaas A, Bruns C, Schmidt T. Cancer-associated fibroblast heterogeneity and its influence on the extracellular matrix and the tumor microenvironment. IJMS. 2023;24(17):13482. https:\/\/doi.org\/10.3390\/ijms241713482.","journal-title":"IJMS"},{"issue":"1","key":"695_CR104","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Sig Transduct Target Ther. 2021;6(1):218. https:\/\/doi.org\/10.1038\/s41392-021-00641-0.","journal-title":"Sig Transduct Target Ther"},{"issue":"1\u20132","key":"695_CR105","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00281-024-01014-9","volume":"46","author":"VLJL Thijssen","year":"2024","unstructured":"Thijssen VLJL. Vascular galectins in tumor angiogenesis and cancer immunity. Semin Immunopathol. 2024;46(1\u20132):3. https:\/\/doi.org\/10.1007\/s00281-024-01014-9.","journal-title":"Semin Immunopathol"},{"issue":"7586","key":"695_CR106","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature17040","volume":"529","author":"S Rafii","year":"2016","unstructured":"Rafii S, Butler JM, Ding BS. Angiocrine functions of organ-specific endothelial cells. Nature. 2016;529(7586):316\u201325. https:\/\/doi.org\/10.1038\/nature17040.","journal-title":"Nature"},{"issue":"1","key":"695_CR107","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev-physiol-021115-105134","volume":"79","author":"M Potente","year":"2017","unstructured":"Potente M, Carmeliet P. The link between angiogenesis and endothelial metabolism. Annu Rev Physiol. 2017;79(1):43\u201366. https:\/\/doi.org\/10.1146\/annurev-physiol-021115-105134.","journal-title":"Annu Rev Physiol"},{"issue":"10","key":"695_CR108","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1111\/cas.13336","volume":"108","author":"N Maishi","year":"2017","unstructured":"Maishi N, Hida K. Tumor endothelial cells accelerate tumor metastasis. Cancer Sci. 2017;108(10):1921\u20136. https:\/\/doi.org\/10.1111\/cas.13336.","journal-title":"Cancer Sci"},{"issue":"1","key":"695_CR109","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1152\/physrev.00046.2024","volume":"106","author":"AM Jordan","year":"2026","unstructured":"Jordan AM, Drake RJG, Hodivala-Dilke KM. Angiocrine and pericrine signaling: how endothelial cells and pericytes drive cancer progression and therapy resistance. Physiol Rev. 2026;106(1):87\u2013119. https:\/\/doi.org\/10.1152\/physrev.00046.2024.","journal-title":"Physiol Rev"},{"issue":"4","key":"695_CR110","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.dsi.2012.10.002","volume":"30","author":"HY Chen","year":"2012","unstructured":"Chen HY, Lo CH, Li CS, Hsu DK, Liu FT. Galectins and cutaneous immunity. Dermatologica Sinica. 2012;30(4):121\u20137. https:\/\/doi.org\/10.1016\/j.dsi.2012.10.002.","journal-title":"Dermatologica Sinica"},{"key":"695_CR111","doi-asserted-by":"publisher","first-page":"1052959","DOI":"10.3389\/fcvm.2023.1052959","volume":"10","author":"L Kruk","year":"2023","unstructured":"Kruk L, Braun A, Cosset E, Gudermann T, Mammadova-Bach E. Galectin functions in cancer-associated inflammation and thrombosis. Front Cardiovasc Med. 2023;10:1052959. https:\/\/doi.org\/10.3389\/fcvm.2023.1052959.","journal-title":"Front Cardiovasc Med"},{"issue":"6558","key":"695_CR112","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/378736a0","volume":"378","author":"NL Perillo","year":"1995","unstructured":"Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature. 1995;378(6558):736\u20139. https:\/\/doi.org\/10.1038\/378736a0.","journal-title":"Nature"},{"issue":"7","key":"695_CR113","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.3390\/ijms24076501","volume":"24","author":"X Yu","year":"2023","unstructured":"Yu X, Qian J, Ding L, Yin S, Zhou L, Zheng S. Galectin-1: a traditionally immunosuppressive protein displays context-dependent capacities. Int J Mol Sci. 2023;24(7):6501. https:\/\/doi.org\/10.3390\/ijms24076501.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"695_CR114","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/sj.cdd.4400708","volume":"7","author":"GA Rabinovich","year":"2000","unstructured":"Rabinovich GA, Alonso CR, Sotomayor CE, Durand S, Bocco JL, Riera CM. Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ. 2000;7(8):747\u201353. https:\/\/doi.org\/10.1038\/sj.cdd.4400708.","journal-title":"Cell Death Differ"},{"issue":"17","key":"695_CR115","doi-asserted-by":"publisher","first-page":"7228","DOI":"10.1158\/0008-5472.CAN-08-1245","volume":"68","author":"W Peng","year":"2008","unstructured":"Peng W, Wang HY, Miyahara Y, Peng G, Wang RF. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 2008;68(17):7228\u201336. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1245. PubMed PMID: 18757439; PubMed Central PMCID: PMC3181121.","journal-title":"Cancer Res"},{"key":"695_CR116","doi-asserted-by":"publisher","first-page":"948098","DOI":"10.1155\/2012\/948098","volume":"2012","author":"NB Hao","year":"2012","unstructured":"Hao NB, L\u00fc MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012;2012:948098. https:\/\/doi.org\/10.1155\/2012\/948098. PubMed PMID: 22778768; PubMed Central PMCID: PMC3385963.","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"695_CR117","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Sig Transduct Target Ther. 2023;8(1):207. https:\/\/doi.org\/10.1038\/s41392-023-01452-1.","journal-title":"Sig Transduct Target Ther"},{"key":"695_CR118","doi-asserted-by":"publisher","unstructured":"Liu Y, Tan H, Dai J, Lin J, Zhao K, Hu H, et al. Targeting macrophages in cancer immunotherapy: frontiers and challenges. J Adv Res. 2025;S2090123224006222. https:\/\/doi.org\/10.1016\/j.jare.2024.12.043.","DOI":"10.1016\/j.jare.2024.12.043"},{"issue":"4","key":"695_CR119","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3892\/etm.2022.11577","volume":"24","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Fang T, Wei S, Chai S, Yang H, Tao M, et al. Macrophages in melanoma: a double\u2013edged sword and targeted therapy strategies (Review). Exp Ther Med. 2022;24(4):640. https:\/\/doi.org\/10.3892\/etm.2022.11577.","journal-title":"Exp Ther Med"},{"issue":"1","key":"695_CR120","doi-asserted-by":"publisher","first-page":"e000832","DOI":"10.1136\/jitc-2020-000832","volume":"9","author":"A Prokopi","year":"2021","unstructured":"Prokopi A, Tripp CH, Tummers B, Hornsteiner F, Spoeck S, Crawford JC, et al. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. J Immunother Cancer. 2021;9(1):e000832. https:\/\/doi.org\/10.1136\/jitc-2020-000832.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"695_CR121","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4331\/wjbc.v2.i9","volume":"2","author":"F Lefranc","year":"2011","unstructured":"Lefranc F, Mathieu V, Kiss R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J Biol Chem. 2011;2(9):193\u2013201. https:\/\/doi.org\/10.4331\/wjbc.v2.i9.","journal-title":"World J Biol Chem"},{"key":"695_CR122","doi-asserted-by":"publisher","first-page":"1250559","DOI":"10.3389\/fimmu.2023.1250559","volume":"14","author":"J Mabbitt","year":"2023","unstructured":"Mabbitt J, Holyer ID, Roper JA, Nilsson UJ, Zetterberg FR, Vuong L, et al. Resistance to anti-PD-1\/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1\/PD-L1. Front Immunol. 2023;14:1250559. https:\/\/doi.org\/10.3389\/fimmu.2023.1250559.","journal-title":"Front Immunol"},{"issue":"11","key":"695_CR123","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/cancers17111888","volume":"17","author":"A Griffiths","year":"2025","unstructured":"Griffiths A, Udomjarumanee P, Georgescu AS, Barri M, Zinovkin DA, Pranjol MZI. The immunomodulatory role of galectin-1 in the tumour microenvironment and strategies for therapeutic applications. Cancers. 2025;17(11):1888. https:\/\/doi.org\/10.3390\/cancers17111888.","journal-title":"Cancers"},{"issue":"1","key":"695_CR124","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4081\/oncol","volume":"11","author":"BS Kalal","year":"2017","unstructured":"Kalal BS, Upadhya D, Pai VR. Chemotherapy resistance mechanisms in advanced skin cancer. Oncol Rev. 2017;11(1):326. https:\/\/doi.org\/10.4081\/oncol.","journal-title":"Oncol Rev"},{"issue":"23","key":"695_CR125","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-18-3870","volume":"26","author":"P Navarro","year":"2020","unstructured":"Navarro P, Mart\u00ednez-Bosch N, Blidner AG, Rabinovich GA. Impact of galectins in resistance to anticancer therapies. Clin Cancer Res. 2020;26(23):6086\u2013101. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3870.","journal-title":"Clin Cancer Res"},{"key":"695_CR126","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coi.2016.12.003","volume":"45","author":"SP M\u00e9ndez-Huergo","year":"2017","unstructured":"M\u00e9ndez-Huergo SP, Blidner AG, Rabinovich GA. Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis. Curr Opin Immunol. 2017;45:8\u201315. https:\/\/doi.org\/10.1016\/j.coi.2016.12.003.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"695_CR127","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/biom10050750","volume":"10","author":"D Compagno","year":"2020","unstructured":"Compagno D, Tiraboschi C, Garcia JD, Rond\u00f3n Y, Corapi E, Velazquez C, et al. Galectins as checkpoints of the immune system in cancers, their clinical relevance, and implication in clinical trials. Biomolecules. 2020;10(5):750. https:\/\/doi.org\/10.3390\/biom10050750.","journal-title":"Biomolecules"},{"issue":"3","key":"695_CR128","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, G\u00f3rska M, Polity\u0144ska B, Wojtukiewicz AM, et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40(3):949\u201382. https:\/\/doi.org\/10.1007\/s10555-021-09976-0.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"695_CR129","doi-asserted-by":"publisher","first-page":"FDD81","DOI":"10.4155\/fdd-2022-0010","volume":"5","author":"PI Back","year":"2023","unstructured":"Back PI, Rascon K, Islam MR, Selby C, La-Beck NM. Targeting immune checkpoint pathways in melanoma: triumphs and challenges. Future Drug Discov. 2023;5(1):FDD81. https:\/\/doi.org\/10.4155\/fdd-2022-0010.","journal-title":"Future Drug Discov"},{"issue":"10","key":"695_CR130","doi-asserted-by":"publisher","first-page":"e009952","DOI":"10.1136\/jitc-2024-009952","volume":"12","author":"SR Greisen","year":"2024","unstructured":"Greisen SR, Bendix M, Nielsen MA, Pedersen K, Jensen NH, Hvid M, et al. Gal-3 blocks the binding between PD-1 and pembrolizumab. J Immunother Cancer. 2024;12(10):e009952. https:\/\/doi.org\/10.1136\/jitc-2024-009952.","journal-title":"J Immunother Cancer"},{"key":"695_CR131","doi-asserted-by":"publisher","first-page":"1104625","DOI":"10.3389\/fimmu.2022.1104625","volume":"13","author":"DJ Laderach","year":"2022","unstructured":"Laderach DJ, Compagno D. Inhibition of galectins in cancer: Biological challenges for their clinical application. Front Immunol. 2022;13:1104625. 10.3389. \/fimmu.2022.1104625 PubMed PMID: 36703969; PubMed Central PMCID: PMC9872792.","journal-title":"Front Immunol"},{"issue":"1\/2","key":"695_CR132","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1023\/A:1013123532723","volume":"20","author":"D Grossman","year":"2001","unstructured":"Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 2001;20(1\/2):3\u201311. https:\/\/doi.org\/10.1023\/A:1013123532723.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"695_CR133","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41419-022-04520-6","volume":"13","author":"P Carabias","year":"2022","unstructured":"Carabias P, Espelt MV, Bacigalupo ML, Rojas P, Sarrias L, Rubin A, et al. Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression. Cell Death Dis. 2022;13(1):79. https:\/\/doi.org\/10.1038\/s41419-022-04520-6.","journal-title":"Cell Death Dis"},{"issue":"11","key":"695_CR134","doi-asserted-by":"publisher","first-page":"e82478","DOI":"10.1371\/journal.pone.0082478","volume":"8","author":"YK Lee","year":"2013","unstructured":"Lee YK, Lin TH, Chang CF, Lo YL. Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via \u03b2-catenin\/GSK-3\u03b2 modulation in colorectal carcinoma. PLoS ONE. 2013;8(11):e82478. https:\/\/doi.org\/10.1371\/journal.pone.0082478.","journal-title":"PLoS ONE"},{"issue":"3","key":"695_CR135","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drup","volume":"10","author":"T Fukumori","year":"2007","unstructured":"Fukumori T, Kanayama HO, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat. 2007;10(3):101\u20138. https:\/\/doi.org\/10.1016\/j.drup.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"695_CR136","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/ijms18010074","volume":"18","author":"K Fujita","year":"2017","unstructured":"Fujita K, Iwama H, Oura K, Tadokoro T, Samukawa E, Sakamoto T, et al. Cancer Therapy due to apoptosis: galectin-9. Int J Mol Sci. 2017;18(1):74. https:\/\/doi.org\/10.3390\/ijms18010074.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"695_CR137","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-014-0062-0","volume":"33","author":"S Kaufhold","year":"2014","unstructured":"Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014;33(1):62. https:\/\/doi.org\/10.1186\/s13046-014-0062-0.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"695_CR138","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cancers12071823","volume":"12","author":"I Proietti","year":"2020","unstructured":"Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, et al. BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancers (Basel). 2020;12(7):1823. https:\/\/doi.org\/10.3390\/cancers12071823.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"695_CR139","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","volume":"18","author":"AM Grimaldi","year":"2017","unstructured":"Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA. MEK inhibitors in the treatment of metastatic melanoma and solid tumors. Am J Clin Dermatol. 2017;18(6):745\u201354. https:\/\/doi.org\/10.1007\/s40257-017-0292-y.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"695_CR140","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.jid.2024.02.011","volume":"144","author":"NBB Mohammed","year":"2024","unstructured":"Mohammed NBB, Lau LS, Souchak J, Qiu S, Ahluwalia MS, Osman I, et al. Tumor-intrinsic Galectin-3 suppresses melanoma metastasis. J Invest Dermatol. 2024;144(9):2039\u2013e20519. https:\/\/doi.org\/10.1016\/j.jid.2024.02.011.","journal-title":"J Invest Dermatology"},{"issue":"9","key":"695_CR141","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3390\/cancers15092408","volume":"15","author":"E Yosefof","year":"2023","unstructured":"Yosefof E, Kurman N, Yaniv D. The role of radiation therapy in the treatment of non-melanoma skin cancer. Cancers (Basel). 2023;15(9):2408. https:\/\/doi.org\/10.3390\/cancers15092408.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"695_CR142","doi-asserted-by":"publisher","first-page":"10511","DOI":"10.4081\/ejtm.2022.10511","volume":"32","author":"A Gonzalez","year":"2022","unstructured":"Gonzalez A, Abrigo J, Achiardi O, Simon F, Cabello-Verrugio C. Intensive care unit-acquired weakness: a review from molecular mechanisms to its impact in COVID-2019. Eur J Transl Myol. 2022;32(3):10511. https:\/\/doi.org\/10.4081\/ejtm.2022.10511.","journal-title":"Eur J Transl Myol"},{"issue":"7","key":"695_CR143","doi-asserted-by":"publisher","first-page":"840","DOI":"10.4161\/cbt.28873","volume":"15","author":"RS Carvalho","year":"2014","unstructured":"Carvalho RS, Fernandes VC, Nepomuceno TC, Rodrigues DC, Woods NT, Suarez-Kurtz G, et al. Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther. 2014;15(7):840\u201350. https:\/\/doi.org\/10.4161\/cbt.28873.","journal-title":"Cancer Biol Ther"},{"issue":"35","key":"695_CR144","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1200\/JCO.2005.02.0206","volume":"23","author":"QT Le","year":"2005","unstructured":"Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. JCO. 2005;23(35):8932\u201341. https:\/\/doi.org\/10.1200\/JCO.2005.02.0206.","journal-title":"JCO"},{"key":"695_CR145","doi-asserted-by":"publisher","unstructured":"Wang H, Jiang H, Van De Gucht M, De Ridder M. Hypoxic radioresistance: can ros be the key to overcome it? Cancers (Basel). 2019;11(1):112. https:\/\/doi.org\/10.3390\/cancers11010112.","DOI":"10.3390\/cancers11010112"},{"issue":"Supplement6","key":"695_CR146","doi-asserted-by":"publisher","first-page":"vi92","DOI":"10.1093\/neuonc\/noz175.380","volume":"21","author":"F Henderson","year":"2019","unstructured":"Henderson F, Das A, Kanginakudru I, McDonald DG, Kosnik Infinger L, Vandergrift Iii W, et al. Exth-48. Galectin-1 inhibition sensitizes radiation treatment in a Pre-clinical model of glioblastoma. Neurooncology. 2019;21(Supplement6):vi92\u201392. https:\/\/doi.org\/10.1093\/neuonc\/noz175.380.","journal-title":"Neurooncology"},{"issue":"9","key":"695_CR147","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ijms17091566","volume":"17","author":"JM Cousin","year":"2016","unstructured":"Cousin JM, Cloninger MJ. The role of galectin-1 in cancer progression, and synthetic multivalent systems for the study of galectin-1. Int J Mol Sci. 2016;17(9):1566. https:\/\/doi.org\/10.3390\/ijms17091566.","journal-title":"Int J Mol Sci"},{"key":"695_CR148","doi-asserted-by":"publisher","unstructured":"Fortuna-Costa A, Gomes AM, Kozlowski EO, Stelling MP, Pav\u00c3\u00a3o MSG. Extracellular galectin-3 in tumor progression and metastasis. Front Oncol. 2014;4. https:\/\/doi.org\/10.3389\/fonc.2014.00138.","DOI":"10.3389\/fonc.2014.00138"},{"issue":"2","key":"695_CR149","doi-asserted-by":"publisher","first-page":"455","DOI":"10.7314\/APJCP.2016.17.2.455","volume":"17","author":"M Kaur","year":"2016","unstructured":"Kaur M, Kaur T, Kamboj SS, Singh J. Roles of Galectin-7 in Cancer. Asian Pac J Cancer Prev. 2016;17(2):455\u201361. https:\/\/doi.org\/10.7314\/APJCP.2016.17.2.455.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"695_CR150","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832. https:\/\/doi.org\/10.1038\/s41467-021-21099-2. PubMed PMID: 33547304; PubMed Central PMCID: PMC7864927.","journal-title":"Nat Commun"},{"issue":"1","key":"695_CR151","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/01.EWX.0000525980.09011.1","volume":"15","author":"NM Abd El-Naby","year":"2018","unstructured":"Abd El-Naby NM, El-Far NN, Shareef MM, El-Husseiny M. Immunohistochemical study of galectin-3 expression in basal cell carcinoma, squamous cell carcinoma, seborrheic keratosis and keratoacanthoma. J Egypt Women\u02bcs Dermatol Soc. 2018;15(1):40\u20136. https:\/\/doi.org\/10.1097\/01.EWX.0000525980.09011.1.","journal-title":"J Egypt Women\u02bcs Dermatol Soc"},{"key":"695_CR152","doi-asserted-by":"publisher","unstructured":"Punt S, Thijssen VL, Vrolijk J, De Kroon CD, Gorter A, Jordanova ES. Galectin-1, -3 and \u2013\u20099 expression and clinical significance in squamous cervical cancer. Busson P, editor. PLoS ONE. 2015;10(6):e0129119. https:\/\/doi.org\/10.1371\/journal.pone.0129119","DOI":"10.1371\/journal.pone.0129119"}],"container-title":["Biological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40659-026-00695-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-026-00695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-026-00695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:09:34Z","timestamp":1783652974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40659-026-00695-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":152,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1186\/s40659-026-00695-w","relation":{},"ISSN":["0717-6287"],"issn-type":[{"value":"0717-6287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}